Formycon AG (ETR:FYB)
22.60
+1.30 (6.10%)
May 29, 2026, 5:35 PM CET
Formycon AG Employees
Formycon AG had 203 employees as of December 31, 2025. The number of employees decreased by 47 or -18.80% compared to the previous year.
Employees
203
Change
-47
Growth
-18.80%
Revenue / Employee
€257,517
Profits / Employee
€280,276
Market Cap
399.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 203 | -47 | -18.80% | 203 | 0 |
| Jun 30, 2025 | 245 | - | - | 245 | 0 |
| Dec 31, 2024 | 250 | 12 | 5.04% | 250 | 0 |
| Dec 31, 2023 | 238 | 33 | 16.10% | 238 | 0 |
| Dec 31, 2022 | 205 | 34 | 19.88% | 205 | 0 |
| Dec 31, 2021 | 171 | 40 | 30.53% | 125 | 46 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 177,783 |
| Bayer Aktiengesellschaft | 87,757 |
| Siemens Healthineers AG | 73,800 |
| Merck KGaA | 59,077 |
| RHÖN-KLINIKUM Aktiengesellschaft | 19,184 |
| MEDICLIN Aktiengesellschaft | 7,416 |
| Evotec SE | 4,526 |
| Redcare Pharmacy NV | 2,163 |
Formycon AG News
- 3 days ago - Formycon AG Earnings Call Transcript: Q1 2026 - Transcripts
- 3 days ago - Formycon AG Earnings release: Q1 2026 - Filings
- 3 days ago - Formycon AG Slides: Q1 2026 - Filings
- 3 days ago - EQS-News: Formycon Reports Positive Operational Progress and Strong Revenue Growth in the First Quarter of 2026 - Wallstreet:Online
- 9 days ago - EQS-AFR: Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements - Wallstreet:Online
- 10 days ago - EQS-News: Formycon invites to conference call on the results of the first quarter of 2026 and announces participation in international investor conferences - Wallstreet:Online
- 12 days ago - EQS-News: Formycon expands commercial portfolio: Aflibercept biosimilars Ahzantive and Baiama are now available in the European Union - Wallstreet:Online
- 5 weeks ago - Formycon AG Earnings Call Transcript: Q4 2025 - Transcripts